![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic γ heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder.
| Abbreviations | ||
| AH | = | AH amyloidosis |
| AL | = | AL amyloidosis |
| CD | = | cluster differentiation |
| FLCs | = | free light chains |
| WBC | = | white blood cell |
| Abbreviations | ||
| AH | = | AH amyloidosis |
| AL | = | AL amyloidosis |
| CD | = | cluster differentiation |
| FLCs | = | free light chains |
| WBC | = | white blood cell |